Psoriasis vulgaris
Information
- Disease name
- Psoriasis vulgaris
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04340076 | Active, not recruiting | Phase 4 | Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis | August 20, 2020 | December 2025 |
| NCT05079256 | Active, not recruiting | N/A | Laser Induced Changes to Innervation and Vascularisation of Psoriatic Skin | December 9, 2022 | July 31, 2024 |
| NCT03662685 | Active, not recruiting | Phase 4 | Immunogenetic Profiling of Goeckerman Therapy in the Treatment of Psoriasis Vulgaris | August 1, 2018 | May 31, 2024 |
| NCT05215561 | Active, not recruiting | Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPP | February 14, 2022 | September 30, 2024 | |
| NCT05185258 | Active, not recruiting | Phase 4 | Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study | February 16, 2022 | November 15, 2025 |
| NCT00277225 | Completed | Phase 1 | A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis Vulgaris | November 1995 | June 1996 |
| NCT00287547 | Completed | Phase 2 | Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris | March 1997 | January 1998 |
| NCT00306878 | Completed | Phase 1 | Phase I Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris | August 1995 | May 1997 |
| NCT00593177 | Completed | Phase 2 | A Safety and Efficacy Study of a Topical Gel for the Treatment of Mild to Moderate Psoriasis | October 2007 | July 2008 |
| NCT00640393 | Completed | Phase 4 | Safety and Efficacy of Combining nbUVB to Etanercept in Patients | April 2008 | March 2010 |
| NCT00640822 | Completed | Phase 3 | Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment Compared With Tacalcitol Ointment in Patients With Psoriasis on the Face and Skin Folds | February 2008 | July 2009 |
| NCT00670241 | Completed | Phase 3 | Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment and the Gel Vehicle Alone in Patients With Psoriasis Vulgaris | April 2008 | April 2009 |
| NCT00691002 | Completed | Phase 3 | Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment in Psoriasis Vulgaris on the Face and Skin Folds | May 2008 | January 2010 |
| NCT00704262 | Completed | Phase 2 | Effect of Calcipotriol Plus Hydrocortisone Ointment on the Adrenal Hormone Balance and Calcium Metabolism in Patients With Psoriasis Vulgaris on the Face and Skin Folds | May 2008 | December 2009 |
| NCT00764751 | Completed | Phase 2 | Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris | September 2008 | January 2009 |
| NCT00816517 | Completed | Phase 1 | Use of Botulinum Toxin to Treat Psoriasis | January 2009 | December 2015 |
| NCT00817219 | Completed | Phase 2 | Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris | July 2009 | December 2011 |
| NCT00833872 | Completed | Phase 1 | LEO 22811 - A Phase 1, Double-Blind, Placebo-controlled, Single and Multiple Oral Dose Study in Healthy Subjects | January 2009 | November 2009 |
| NCT00845481 | Completed | Phase 2 | A Plaque Test Comparing the Anti-psoriatic Effect of Marketed Products for Topical Use for Psoriasis Vulgaris | January 2009 | May 2009 |
| NCT00875277 | Completed | Phase 2 | A Psoriasis Plaque Test With LEO 29102 Cream and Its Combination Products | April 2009 | July 2009 |
| NCT01007591 | Completed | Phase 3 | A Study Comparing LEO 80190 Ointment With Hydrocortisone Ointment, Both Applied Once Daily in the Treatment of Psoriasis Vulgaris on the Face and Intertriginous Areas | October 2009 | December 2010 |
| NCT01022502 | Completed | Phase 2 | Comparison of Refined and Crude Indigo Naturalis Ointment in Treating Psoriasis | November 2009 | December 2010 |
| NCT01043224 | Completed | Phase 1 | A Psoriasis Plaque Test Comparing Products for the Treatment of Psoriasis Vulgaris | January 2010 | March 2010 |
| NCT01072383 | Completed | Phase 2 | Safety and Efficacy of Multiple Doses of BT061 in Patients With Moderate to Severe Chronic Plaque Psoriasis | February 2010 | August 2011 |
| NCT01105286 | Completed | Phase 1 | A Psoriasis Plaque Test Comparing Eight Different Formulations of Vitamin D Analogues for the Treatment of Psoriasis | April 2010 | June 2010 |
| NCT01116895 | Completed | Phase 2 | A Proof of Concept Study Comparing Three Doses of an Oral Solution of LEO 22811 With a Placebo Oral Solution for the Treatment of Psoriasis Vulgaris | May 2010 | July 2011 |
| NCT01188928 | Completed | Phase 3 | LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs) | September 2010 | March 2011 |
| NCT01229098 | Completed | Phase 2 | Effect of LEO 80185 Gel on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis Vulgaris | October 2010 | October 2011 |
| NCT01268527 | Completed | Phase 2 | A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of Topical E6201 Gel in Subjects With Psoriasis Vulgaris | March 15, 2010 | December 11, 2010 |
| NCT01297166 | Completed | Phase 1 | A Psoriasis Plaque Test on LEO 27989 Ointment and Calcipotriol Plus LEO 27989 Ointment in Patients With Psoriasis Vulgaris | February 2011 | April 2011 |
| NCT01320774 | Completed | Efficacy, Tolerability and Handling of Daivobet® Gel in Patients With Psoriasis Vulgaris | April 2011 | January 2012 | |
| NCT01347255 | Completed | Phase 2 | A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray, Ointment, in Psoriasis Vulgaris | May 2011 | June 2011 |
| NCT01465282 | Completed | Phase 2 | Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris | December 2011 | September 2012 |
| NCT01466478 | Completed | Phase 1 | An Exploratory Psoriasis Plaque Test Study With LEO 29102 Plus Calcipotriol, Ointment, in Psoriasis Vulgaris | November 2011 | December 2011 |
| NCT01536886 | Completed | Phase 2 | LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris | May 2012 | November 2012 |
| NCT01536938 | Completed | Phase 2 | LEO 90100 in the Treatment of Psoriasis Vulgaris | May 2012 | November 2012 |
| NCT01580488 | Completed | Phase 1 | A Plaque Test Study With LEO 35299 in Psoriasis Vulgaris | April 2012 | June 2012 |
| NCT01600222 | Completed | Phase 2 | Effect of LEO 90100 on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis VulgarisExtensive Psoriasis Vulgaris | May 2012 | May 2013 |
| NCT01607853 | Completed | Phase 2 | A Short-contact Plaque Test Study With Daivobet® Gel in Psoriasis Vulgaris | June 2012 | October 2012 |
| NCT01707368 | Completed | Non-interventional Study of Long-term Treatment of Psoriasis With Calcipotriol Plus Betamethasone in Gel Formulation | October 2012 | July 2014 | |
| NCT00220025 | Completed | Phase 1 | Narrowband UVB Light Therapy to Patients With Dark Skin Types Who Have 10% of Their Body Involved With Psoriasis Vulgaris. | June 1999 | May 2009 |
| NCT00236171 | Completed | N/A | Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test | September 2004 | June 2010 |
| NCT00248456 | Completed | Phase 4 | Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Ointment in Patients With Psoriasis Vulgaris | October 2005 | February 2006 |
| NCT00263718 | Completed | Phase 2 | Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Psoriasis Vulgaris | December 2005 | May 2006 |
| NCT02735187 | Completed | N/A | Efficacy and Safety of Blue Light (453 nm) Treatment for Mild Psoriasis Vulgaris Over Three Months Compared to Vitamin D. | March 2016 | August 2016 |
| NCT02796053 | Completed | Phase 1/Phase 2 | TAB08 in Patients With Psoriasis Vulgaris, Not Adequately Controlled With Current Treatment | April 2016 | December 2016 |
| NCT02888236 | Completed | Phase 2 | LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris | September 2016 | July 6, 2017 |
| NCT02899962 | Completed | Phase 3 | LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris | February 15, 2017 | June 26, 2019 |
| NCT02902861 | Completed | Phase 3 | Trial in Patients With Psoriasis Treated With Methotrexate Using an Optimized Treatment Schedule (METOP) | February 2013 | May 2015 |
| NCT02935582 | Completed | PSOREAL - Managing PSOriasis in the REAL World | January 2017 | December 30, 2020 | |
| NCT02973776 | Completed | Phase 1 | Vasoconstriction Trial With LEO 90100 Aerosol Foam | December 2016 | February 2017 |
| NCT02990624 | Completed | N/A | Cardiovascular Risk Evaluation in Psoriasis Treated With Photochemotherapy | April 2014 | October 2015 |
| NCT03022617 | Completed | Phase 4 | A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis | January 2017 | September 29, 2022 |
| NCT03025282 | Completed | Phase 2 | Safety and Efficacy of CD10367 in Psoriasis Vulgaris | November 3, 2016 | March 24, 2017 |
| NCT03069144 | Completed | Phase 1/Phase 2 | Efficacy and Tolerability of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis | January 6, 2012 | May 28, 2012 |
| NCT03149900 | Completed | Exploratory Evaluation of Biomarkers Associated With Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients | October 2016 | July 25, 2019 | |
| NCT03231124 | Completed | Phase 1 | Multiple Dose Study With Incremental Dosing to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Doses of LEO 32731 in Healthy Male Japanese Subjects. | July 25, 2017 | August 22, 2017 |
| NCT03308799 | Completed | Phase 3 | A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream | October 3, 2017 | June 8, 2018 |
| NCT03322137 | Completed | Phase 2 | Safety, Efficacy, and Tolerability of SNA-120 in Subjects With Pruritus Associated With Psoriasis Vulgaris | October 10, 2017 | October 22, 2018 |
| NCT03331835 | Completed | Phase 4 | A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis | November 3, 2017 | March 21, 2019 |
| NCT03348462 | Completed | Phase 4 | Formulation and Clinical Evaluation of Ethosomal and Liposomal Preparations of Anthralin in Psoriasis | November 30, 2017 | January 15, 2020 |
| NCT03359577 | Completed | N/A | Clinical Study to Investigate Psorax35 Supplementation in Patients With Psoriasis | November 21, 2017 | April 29, 2019 |
| NCT03372811 | Completed | Phase 2 | Efficacy and Safety of TC Cream In Treating Patients With Psoriasis Vulgaris | June 11, 2015 | June 30, 2018 |
| NCT03389984 | Completed | N/A | Psoriatic Inflammation Markers Predictive of Response to Adalimumab | November 14, 2017 | June 18, 2020 |
| NCT03402828 | Completed | Body PSOriasis: Long-term Relapse CONTROL | June 11, 2018 | May 15, 2020 | |
| NCT03442244 | Completed | Phase 1 | Skin Irritation of LEO 90100 Foam (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects | January 30, 2018 | February 20, 2018 |
| NCT03462927 | Completed | Phase 2 | A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream | February 8, 2018 | August 4, 2018 |
| NCT03584360 | Completed | Phase 2 | Role of Topical Treatments in the Modulation of Skin Microbiome in Psoriatic Skin | September 24, 2018 | March 7, 2019 |
| NCT03614078 | Completed | Phase 2 | A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis | September 25, 2018 | July 8, 2019 |
| NCT03669757 | Completed | Phase 1 | Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis | September 27, 2018 | February 1, 2019 |
| NCT03731091 | Completed | Phase 3 | To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis). | October 31, 2018 | March 17, 2020 |
| NCT03795402 | Completed | Analysis of Non-Invasively Collected Microneedle Device Samples From Mild Plaque Psoriasis for Use in Transcriptomics Profiling | March 15, 2019 | December 6, 2019 | |
| NCT03802344 | Completed | Phase 3 | This Trial is a Randomised, Multicentre, Investigator-blind, Vehicle and Comparator-controlled, Parallel-group Trial With the Purpose of Evaluation Efficacy, Safety and Convenience of the MC2-01 Cream | December 12, 2018 | October 2, 2019 |
| NCT03806790 | Completed | Phase 3 | Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris | January 24, 2019 | June 10, 2019 |
| NCT03807453 | Completed | Comparison of Scalp Microbiota of the Psoriasis and Seborrheic Dermatitis Patients | April 25, 2019 | June 18, 2019 | |
| NCT03816917 | Completed | Discovery of Arthritis in Psoriasis Patients for Early Rheumatological Referral | June 1, 2019 | July 28, 2022 | |
| NCT03828643 | Completed | Secukinumab Efficacy Without the Initial Loading Dose in Patients With Psoriasis | March 20, 2019 | April 12, 2019 | |
| NCT03885089 | Completed | Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Psoriasis) | October 21, 2019 | March 8, 2024 | |
| NCT03898583 | Completed | Phase 1 | Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamics Effect of Calcipotriol/Betamethasone Dipropionate in a New Administration Form in Subjects With Chronic Plaque Psoriasis. | April 15, 2019 | October 29, 2019 |
| NCT03932110 | Completed | N/A | Metabolic Syndrome in Psoriasis and Psoriatic Arthritis and Correlation With Serum Omentin and Visfatin Levels | April 15, 2019 | June 14, 2019 |
| NCT04080648 | Completed | Phase 4 | Therapeutic Drug Monitoring of Guselkumab in Psoriasis Patients | June 27, 2018 | December 31, 2023 |
| NCT04080661 | Completed | Phase 4 | Therapeutic Drug Monitoring of Secukinumab in Psoriasis Patients. | March 22, 2018 | December 31, 2023 |
| NCT04083612 | Completed | Phase 4 | Therapeutic Drug Monitoring of Ixekizumab in Psoriasis Patients | May 4, 2020 | December 31, 2023 |
| NCT04095130 | Completed | Tissue Sodium in Patients With Psoriasis | July 1, 2015 | September 17, 2019 | |
| NCT04136314 | Completed | N/A | Impact of Decision-Framing in Psoriasis | October 21, 2019 | January 31, 2020 |
| NCT04183881 | Completed | Phase 4 | A Phase 4 Clinical Study of Brodalumab | July 4, 2016 | July 24, 2017 |
| NCT04207216 | Completed | Use of Alternative Therapy in Psoriasis Vulgaris Patients | January 1, 2020 | July 1, 2020 | |
| NCT04207242 | Completed | Social Media Use of Psoriasis Vulgaris Patients: Multicenter, Survey Work | January 1, 2020 | July 1, 2020 | |
| NCT04220554 | Completed | N/A | Improvement of Psoriasis Patients' Adherence to Topical Drugs | June 19, 2020 | June 1, 2022 |
| NCT04343586 | Completed | N/A | Blue Light Phototherapy | September 1, 2020 | September 22, 2022 |
| NCT04418791 | Completed | N/A | Modified Intermittent Fasting in Psoriasis | October 17, 2020 | February 23, 2022 |
| NCT04472546 | Completed | N/A | Use of the SpiderMass for in Vivo Analysis of the Skin in Five Chronic Inflammatory Dermatosis | December 13, 2019 | February 2, 2024 |
| NCT04541329 | Completed | Phase 4 | Predicting Inflammatory Skin Disease Response to IL-23 Blockade | September 16, 2020 | January 15, 2023 |
| NCT04989296 | Completed | N/A | Informative Value of Determining the Level of NF-κB Translocation in Lymphocyte Populations in Children With Psoriasis | September 1, 2018 | January 15, 2020 |
| NCT05120297 | Completed | Phase 3 | A Phase 3 Study of Efficacy and Safety of AK101 in Subjects With Psoriasis | November 29, 2021 | September 29, 2022 |
| NCT05184348 | Completed | Phase 1 | Plexin B2 Gene Expression and Polymorphisms in Psoriasis | September 1, 2021 | March 30, 2023 |
| NCT05461456 | Completed | Phase 1 | Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1% | April 1, 2022 | October 16, 2022 |
| NCT05488990 | Completed | Phase 1/Phase 2 | Efficacy and Safety of Novel Formulations of Topical Calcipotriol in Patients With Mild to Moderate Plaque Psoriasis | March 25, 2013 | June 17, 2013 |
| NCT05647187 | Completed | N/A | Effect Narrow-Band UVB Radiations | January 1, 2020 | October 1, 2021 |
| NCT06011083 | Completed | N/A | Topical Calcipotriol /Betamethasone Ointment in the Treatment of Plaque Psoriasis | August 1, 2022 | August 1, 2023 |
| NCT06042647 | Completed | Phase 4 | Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis | July 13, 2023 | November 13, 2023 |
| NCT06064084 | Completed | Incretin Effect in Patients With Psoriasis and Controls | September 11, 2011 | September 11, 2015 | |
| NCT00216892 | Completed | Phase 4 | Efficacy and Safety of Calcipotriol Cream and (Calcipotriol + Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris | April 2005 | December 2005 |
| NCT01735864 | Completed | N/A | Dosage Determination Trial for Indigo Naturalis Extract in Oil Ointment | November 2012 | April 2014 |
| NCT01743118 | Completed | Phase 1 | Antipsoriatic Effect of a Topical Formulation for the Treatment of Psoriasis Vulgaris | March 2013 | July 2013 |
| NCT01768013 | Completed | Phase 1/Phase 2 | The Pharmacokinetics of LEO 90105 (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Extensive Psoriasis Vulgaris | July 2012 | October 2012 |
| NCT01831466 | Completed | Phase 2 | Tofacitinib Ointment For Chronic Plaque Psoriasis | May 2013 | September 2014 |
| NCT01837576 | Completed | Phase 1 | An Exploratory Psoriasis Plaque Test Study With Different Dose Combinations of Calcipotriol Plus Betamethasone Dipropionate in the Daivobet® Gel Vehicle in Psoriasis Vulgaris | April 2013 | June 2013 |
| NCT01866163 | Completed | Phase 3 | LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris | June 2013 | November 2013 |
| NCT01935869 | Completed | Phase 1 | Combined Cumulative Irritation Potential and Repeat Insult Patch Test of LEO 90100 | August 2013 | December 2013 |
| NCT01936337 | Completed | Phase 2 | Topical Double-blind, Randomized, Placebo-controlled Study in Psoriasis Patients | August 2013 | July 2014 |
| NCT01946386 | Completed | Phase 1 | A Vasoconstriction Study With LEO 90100 | September 2013 | October 2013 |
| NCT01982552 | Completed | An Observational Study to Assess Patient Satisfaction and Control of Psoriasis With Calcipotriene/Betamethasone Dipropionate (Taclonex®) Topical Suspension, and Effect on Quality of Life | July 2013 | January 2014 | |
| NCT02004574 | Completed | Phase 4 | Study for Treatment With Calcipotriol/Betamethasone Dipropionate Gel in Korean Patients With Psoriasis Vulgaris | October 2013 | June 2014 |
| NCT02004847 | Completed | N/A | Blue Light for Treating Psoriasis Vulgaris | September 2013 | May 2014 |
| NCT02038569 | Completed | Phase 2 | An International, Multi-centre, Prospective, Non-controlled, Open, Single-group, 8-week Trial in Adolescent Subjects | January 2014 | February 13, 2018 |
| NCT02052609 | Completed | Phase 3 | A Phase 3 Clinical Study of KHK 4827 | February 2014 | July 4, 2016 |
| NCT02088281 | Completed | Phase 2 | Mechanistic Study of Indigo Naturalis in Treating Psoriasis | November 2012 | July 2013 |
| NCT02106195 | Completed | Phase 2 | A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis Vulgaris | April 2014 | September 2014 |
| NCT02125279 | Completed | Phase 4 | Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis | May 2014 | May 2018 |
| NCT02126371 | Completed | Phase 1 | LP0058-1005 - A Open-Label, Four-Way Crossover and Food-Effect Study of LEO 32731 in Healthy Subjects | May 2014 | January 2015 |
| NCT02132936 | Completed | Phase 3 | LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris | June 2014 | February 2015 |
| NCT02193815 | Completed | Phase 1 | A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis | September 2014 | February 2015 |
| NCT02310646 | Completed | Phase 3 | Patient Insights Following Use of LEO 90100 Aerosol Foam and Daivobet® Gel in Subjects With Psoriasis Vulgaris | January 2015 | July 2015 |
| NCT02317627 | Completed | Phase 2 | Phase 2, Open-label, Study of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-line Therapy | December 2014 | March 2016 |
| NCT02387853 | Completed | Phase 2 | Safety and Efficacy of Once Daily Topical Treatment With LEO 90100 Aerosol Foam in Adolescent Subjects With Plaque Psoriasis | March 2016 | March 28, 2018 |
| NCT02514694 | Completed | Phase 1 | LEO 32731 - A Phase I Study in Healthy Subjects | July 2015 | December 2015 |
| NCT02533973 | Completed | Phase 4 | Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population | September 2015 | March 6, 2018 |
| NCT02577185 | Completed | Phase 1 | An Exploratory Trial Investigating the Neurogenic Component in Psoriasis Vulgaris by Use of Botulinum Toxin A | November 2015 | July 2016 |
| NCT02605057 | Completed | Phase 1 | Dermatopharmacokinetic Trial of LEO 80185 Gel | November 2015 | July 2016 |
| NCT02636101 | Completed | Xamiol®Gel in BODY Psoriasis: A One-year Non-interventional Study | January 2016 | February 15, 2018 | |
| NCT02668692 | Completed | Phase 3 | LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis | February 2016 | June 2016 |
| NCT06398106 | Not yet recruiting | Phase 4 | Proactive TDM Versus Standard Use of Biologics in Psoriasis | September 1, 2024 | March 1, 2028 |
| NCT06414382 | Not yet recruiting | N/A | PSODEEP2 Pilot Study on Koebner Induction in Psoriasis | May 7, 2024 | March 7, 2025 |
| NCT06203470 | Not yet recruiting | Phase 4 | Botox Versus Tacrolimus in Psoriasis Vulgaris | June 2024 | October 2026 |
| NCT05716152 | Not yet recruiting | Hormonal Associations in Male Patients With Psoriasis Vulgaris | February 1, 2023 | August 1, 2024 | |
| NCT05815797 | Not yet recruiting | Phase 2 | Shuiniujiao Dihuang Decoction With Variation for the Treatment of Psoriasis | May 2024 | October 2025 |
| NCT03507946 | Not yet recruiting | N/A | Safety and Effectiveness of Combined LED Light for the Treatment of Mild to Moderate Plaque Type Psoriasis Vulgaris | January 2023 | June 2024 |
| NCT05858645 | Not yet recruiting | Phase 4 | Correction of Psoriatic T Cell Signatures by Deucravacitinib | July 2023 | June 2026 |
| NCT05243303 | Recruiting | N/A | Augmenting Standard-of-care Treatment of Plaque Psoriasis by Neuromodulation | April 26, 2022 | February 28, 2026 |
| NCT05390515 | Recruiting | Phase 4 | Psoriatic Immune Response to Tildrakizumab | September 1, 2022 | September 1, 2025 |
| NCT05906498 | Recruiting | Phase 3 | Using Acetylcysteine and Vitamin E With Psoriasis Vulgaris | December 1, 2022 | December 2023 |
| NCT04994951 | Recruiting | Phase 2 | Pilot Study of Traditional Chinese Medicine (Qing-Re-Liang-Xue Decoction) as Complementary Medicine for Psoriasis Vulgaris of Blood-heat Syndrome. | September 2021 | July 2024 |
| NCT05892640 | Recruiting | N/A | Low-Salt Diet Effect on Th17-Mediated Inflammation and Vascular Reactivity in Psoriasis | September 1, 2022 | June 30, 2024 |
| NCT04080635 | Recruiting | N/A | Therapeutic Drug Monitoring of Brodalumab in Psoriasis Patients (BIOLOPTIM-BRO) | December 14, 2018 | December 31, 2024 |
| NCT05442190 | Recruiting | Phase 2 | Topical SGX302 for Mild-to-Moderate Psoriasis | December 14, 2022 | June 2025 |
| NCT06191042 | Recruiting | Phase 1 | A Study to Evaluate the Safety and Tolerability, and the Efficacy of Si-544 in Adults With Psoriasis Vulgaris or Psoriatic Arthritis | January 22, 2024 | September 30, 2024 |
| NCT05506644 | Recruiting | N/A | Biofeedback for Psoriasis | June 7, 2022 | March 31, 2023 |
| NCT06257641 | Recruiting | N/A | Impact of the Mediterranean Diet on Patients With Psoriasis | October 4, 2023 | April 30, 2025 |
| NCT05683015 | Recruiting | Phase 4 | Therapeutic Drug Monitoring of Tildrakizumab in Psoriasis Patients | August 22, 2022 | December 31, 2025 |
| NCT05685940 | Recruiting | Phase 4 | Therapeutic Drug Monitoring of Risankizumab in Psoriasis Patients (BIOLOPTIM-RIS) | April 5, 2020 | December 31, 2024 |
| NCT05820698 | Recruiting | N/A | The Mediterranean Diet and Time-Restricted Eating Dietary Interventions for Psoriasis Study | June 8, 2023 | August 1, 2024 |
| NCT04950218 | Recruiting | The Psoriasis Echo Study | September 1, 2021 | October 1, 2030 | |
| NCT04306315 | Recruiting | Phase 4 | Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight | July 18, 2022 | January 8, 2026 |
| NCT05102474 | Recruiting | Dermatologic Research Evaluation and Monitoring of Sleep in Moderate-to-Severe Psoriasis | February 15, 2022 | May 31, 2024 | |
| NCT02753218 | Terminated | Phase 1 | A Phase I Study With LEO 32731 and Midazolam in Healthy Male Subjects | April 2016 | May 2016 |
| NCT04028713 | Terminated | Phase 4 | Dose Tapering Study of Adalimumab in Psoriasis | February 16, 2021 | March 22, 2022 |
| NCT04533737 | Terminated | Phase 4 | Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab | December 17, 2020 | December 7, 2022 |
| NCT03819218 | Terminated | Phase 2 | A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream in Adolescent Subjects | December 27, 2018 | December 11, 2020 |
| NCT00924950 | Terminated | Phase 4 | Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis | June 2009 | December 2009 |
| NCT04740983 | Unknown status | N/A | Ultraviolet Radiation Forecasting Based Heliotherapy For Psoriasis in Bangkok, Thailand | March 15, 2021 | December 31, 2021 |
| NCT01702324 | Unknown status | Phase 1/Phase 2 | Evaluation of DD-25 Topical Cream for the Treatment of Psoriasis Vulgaris : Proof of Concept Study | October 2012 | September 2013 |
| NCT04750161 | Unknown status | The Role Of Neutrophil Proteases As Global Regulators Of Il-1 Family Cytokine Activity In Skin Disorders | March 2, 2021 | June 2021 | |
| NCT03408756 | Unknown status | Phase 4 | Comparison of Oral Versus Subcutaneous Route of Methotrexate Administration in Moderate to Severe Psoriasis | April 1, 2018 | December 30, 2019 |
| NCT01753245 | Unknown status | Analysis Of The Influence Of Metabolic Syndrome On Treatment Efficacy With Anti-Tnf In Moderate-Severe Psoriasis In Real Clinical Practice. | December 2012 | June 2014 | |
| NCT03469219 | Unknown status | Serum Granulysin Level as a Marker to Detect the Severity of Psoriasis | July 2018 | March 2019 | |
| NCT03553433 | Unknown status | Phase 4 | Apremilast Treatment for Pruritus and Quality of Life in Scalp Psoriasis | June 2018 | June 2020 |
| NCT01443338 | Unknown status | Phase 4 | Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Psoriasis Vulgaris - CHINA201002016-2 | September 2011 | |
| NCT03675542 | Unknown status | Phase 1 | The Safety and Efficacy of a Novel HSP90 Inhibitor (CUDC-305) in the Treatment of Moderate to Severe Psoriasis. | November 1, 2018 | February 1, 2020 |
| NCT05144165 | Unknown status | Systemic Treatment of Moderate-to-severe Psoriasis in Adults: Update of the French Guidelines | November 8, 2021 | March 31, 2022 | |
| NCT00678756 | Unknown status | Phase 2 | Investigation of Antipsoriatic Effects of UVB-induced Synthesis of 1alpha, 25-Dihydroxyvitamin D3 (1alpha, 25(OH)2D3, Calcitriol)in Keratinocytes of Psoriatic Skin, Using Cytochrom-P(CYP)Inhibitor Ketokonazol | March 2008 | December 2009 |
| NCT00365625 | Unknown status | Determination of Lymphocyte JAM-C Expression in Patients With Psoriasis Vulgaris | July 2005 | December 2007 | |
| NCT05254249 | Unknown status | Phase 1/Phase 2 | Clinical Trial of Probiotic Supplementation in Psoriasis Vulgaris | February 7, 2022 | October 2022 |
| NCT03874975 | Unknown status | Early Phase 1 | Combined Oral Vitamin D and UVB Versus UVB Alone in Treatment of Psoriasis Vulgaris | April 1, 2019 | April 1, 2020 |
| NCT05279638 | Unknown status | ATG5 as a Serum Marker of Autophagy in Psoriatic Patient | February 1, 2022 | January 1, 2024 | |
| NCT05311501 | Unknown status | N/A | Impact of Non-surgical Periodontal Therapy in the Management of Plaque Psoriasis. | May 10, 2022 | January 1, 2023 |
| NCT02491658 | Unknown status | Phase 1/Phase 2 | Safety and Efficacy of UC-MSCs in Patients With Psoriasis Vulgaris | April 2015 | December 2016 |
| NCT03942198 | Unknown status | Phase 2 | Oral Chinese Herbal Medicine for Psoriasis Vulgaris With Blood Stasis Syndrome | June 1, 2019 | December 31, 2021 |
| NCT03961230 | Unknown status | Phase 2 | Oral Chinese Herbal Medicine for Psoriasis Vulgaris With Blood Heat Syndrome | June 1, 2019 | December 31, 2021 |
| NCT02715947 | Unknown status | Phase 2 | Pharmacogenomics Study on Treatment of Psoriasis Vulgaris by Methotrexate | December 2015 | December 2017 |
| NCT02715960 | Unknown status | Phase 2 | Pharmacogenomics Study on Treatment of Psoriasis Vulgaris by Acitretin Capsules | December 2015 | December 2017 |
| NCT04099979 | Unknown status | A Pilot Study to Explore the Role of Gut Flora in Psoriasis | March 2, 2020 | July 2023 | |
| NCT04242082 | Unknown status | Glucose Trnsporter and PEDF in Psoriasis | July 31, 2020 | March 1, 2021 | |
| NCT01339741 | Unknown status | N/A | Efficacy of Vitamin D3 for the Treatment of Psoriatic Patients With Vitamin D Deficiency and Insufficiency | March 2011 | February 2012 |
| NCT03307447 | Unknown status | Phase 4 | Secukinumab Therapy for the Treatment of Moderate to Severe Plaque Psoriasis With Response Monitoring Using Optical Coherence Tomography (OCT). | December 19, 2017 | December 2021 |
| NCT04394936 | Unknown status | N/A | An Explorative Psoriasis Biomarker Study | September 1, 2020 | December 2022 |
| NCT04493762 | Unknown status | Liver Fibrosis and Gut Microbiota in Patients With Psoriasis Vulgaris and Rheumatoid Arthritis on Methotrexate | August 13, 2020 | December 11, 2022 | |
| NCT01651559 | Unknown status | The Efficacy Of A Dead Sea Mineral Enriched Body Cream vs Its Carrier as an Adjuvant Treatment For Psoriatic Patients | November 2012 | June 2013 | |
| NCT03979664 | Withdrawn | Early Phase 1 | Iontophoresis in Psoriasis | March 2021 | December 2021 |
| NCT05499416 | Withdrawn | Phase 4 | Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis | January 2023 | April 2024 |
- MedGen concept unique identifier (MedGen Concept name)
- C0263361
- MedGen unique identifier (MedGen Concept name)
- 537842
- ICD10 preferred id (Insert disease from ICD10)
- D0009751
- ICD10 class code (Insert disease from ICD10)
- L40.0